A quantitative positron emission tomographic (PET) method to measure amino acid blood-brain barrier (BBB) transport rate and tissue distribution volume (DV) has been developed using IIC-Iabeled aminocyciohex anecarboxylate (ACHC), a nonmetabolized amino acid analogue. Dynamic PET data were acquired as a series of 15 scans covering a total of 60 min and analyzed by means of a two-compartment, two-parameter model. Functional images were calculated for the amino acid transport rate constants across the BBB and the amino acid DV in the brain. Results show [IIC]ACHC to have an influx rate constant in gray matter of � 0 . 03-{1. 04 ml g-I min -I, indi cating a single-pass extraction fraction of �5-7%. The Amino acids are transported across the blood brain barrier (BBB) by specific saturable carriers (Oldendorf, 1971) . Of particular importance is the large neutral amino acid (LNAA) uptake system for brain amino acids since it mediates the entry of es sential amino acids into the brain for synthesis of proteins and of catecholamine and indoleamine neu rotransmitters . Regional transport or uptake rates and amino acid distribution volumes (nVs) can be measured in humans by analysis of the in vivo ki-727 intersubject coefficient of variation was � 15% while in trasubject variability of repeat scans was only slightly greater than 5%. Studies were performed in 15 young normal volunteer control subjects, 5 elderly controls, 7 patients with probable Alzheimer'S disease, and one pa tient with phenylketonuria. Results indicate that P lC]_ ACHC will serve as the basis of a method for measuring amino acid transport rate and DV in the normal and pathological human brain. Key Words: Amino acid trans port-Aminocyciohexanecarboxylate-Blood-brain bar rier-Brain-Positron emission tomography-Tracer ki netic modeling.
Summary: A quantitative positron emission tomographic (PET) method to measure amino acid blood-brain barrier (BBB) transport rate and tissue distribution volume (DV) has been developed using IIC-Iabeled aminocyciohex anecarboxylate (ACHC), a nonmetabolized amino acid analogue. Dynamic PET data were acquired as a series of 15 scans covering a total of 60 min and analyzed by means of a two-compartment, two-parameter model. Functional images were calculated for the amino acid transport rate constants across the BBB and the amino acid DV in the brain. Results show [IIC]ACHC to have an influx rate constant in gray matter of � 0 . 03-{1. 04 ml g-I min -I, indi cating a single-pass extraction fraction of �5-7%. The Amino acids are transported across the blood brain barrier (BBB) by specific saturable carriers (Oldendorf, 1971) . Of particular importance is the large neutral amino acid (LNAA) uptake system for brain amino acids since it mediates the entry of es sential amino acids into the brain for synthesis of proteins and of catecholamine and indoleamine neu rotransmitters . Regional transport or uptake rates and amino acid distribution volumes (nVs) can be measured in humans by analysis of the in vivo ki-intersubject coefficient of variation was � 15% while in trasubject variability of repeat scans was only slightly greater than 5%. Studies were performed in 15 young normal volunteer control subjects, 5 elderly controls, 7 patients with probable Alzheimer'S disease, and one pa tient with phenylketonuria. Results indicate that P lC]_ ACHC will serve as the basis of a method for measuring amino acid transport rate and DV in the normal and pathological human brain. Key Words: Amino acid trans port-Aminocyciohexanecarboxylate-Blood-brain bar rier-Brain-Positron emission tomography-Tracer ki netic modeling.
netics of a labeled amino acid using positron emis sion tomography (PET) . Most PET studies with amino acids thus far have employed labeled natural amino acids such as L-leucine (Hawkins, 1989) or L-methionine (Bustany et aI ., 1986; Bergstrom et aI ., 1987; O'Tuama et aI., 1988) . However, interpre tation of experiments that use labeled natural amino acids for determining transport kinetics is compli cated by their metabolism and incorporation into proteins. These processes can lead to uncertainties in the measurements of both amino acid uptake (in flux) and clearance (efflux) rate constants.
The use of synthetic amino acids that are neither metabolized nor incorporated into proteins can al leviate these problems. An example of a synthetic amino acid analogue commonly used to study amino acid transport in cells is l-aminocyclopen tanecarboxylate (ACPC; Oxender and Christensen, 1963; Christensen, 1973) . ACPC has been shown to be transported in the rodent brain by the same neu tral amino acid carrier at the BBB as many other natural amino acids, such as leucine and methionine (Pardridge and Oldendorf, 1975) , but with an affin ity for the carrier that is approximately an order of magnitude lower than that of L-Ieucine (Smith and Takasato, 1986) . Thus, uptake of a positron emit ter-labeled ACPC would not be expected to provide useful tomographic images or kinetic information concerning brain amino acid uptake. Washburn et al. (1981) proposed the use of a hom ologue of ACPC based on a cyclohexane rather than a cyclopentane ring, l-aminocyclohexanecarboxy late (ACHC), with the prediction that it would have a greater affinity than ACPC for the neutral amino acid carrier system because of its increased hydro phobicity. Subsequent studies in rats using [ 14 C]_ ACHC by Aoyagi et al. (1988) demonstrated that the Vm a x (7.7 X 10-4 f.1mol S-I g-I ) and Km (53 f.1M) of ACHC are similar to those of many of the natural amino acids transported by the L-amino acid car rier, being close to those of tyrosine (1.6 x 10-3 f.1mol S-I g-I ; 64 f.1M), isoleucine 0.0 x 10 -3 f.1mol S-I g-I ; 56 f.1M) and methionine (4.2 x 10 -4 f.1mol s -1 g -I ; 40 f.1M). Their data also confirm earlier work that ACHC, like ACPC (Christensen and Jones, 1962; Sterling et aI., 1962) , is neither metab olized nor utilized for protein synthesis, and fu rther is the preferred radiotracer for PET studies on brain amino acid uptake. These prior studies showed that no substantial amounts of ACHC or ACPC metab olites are present in either brain or blood, even up to several days after administration.
The purpose of the present study was to evaluate the utility of [ ll C]ACHC for the measurement of regional amino acid uptake and clearance rates and the amino acid DV in human brain using dynamic PET scanning and tracer kinetic modeling. We present here a kinetic model used in the analysis of ACHC data and discuss its implementation for dy namic PET. We also present simulation studies in dicating the predicted accuracy of the estimated ki netic parameters and discuss the strengths and lim itations of the kinetic model. Results are reported for initial clinical applications in controls of differ ing ages, patients with a degenerative brain disorder (Alzheimer'S disease; AD), and a patient with an inherited disorder of amino acid metabolism, phe nylketonuria (PKU). Figure 1 depicts the tracer kinetic model used in the present study. It consists of two compartments: arterial plasma and brain tissue with radio tracer concentrations of C p and Cf, respectively. Intracel lular and extracellular spaces in the brain are as- Vol. 10, No.5, 1990 AMINO ACID UPTAKE KINETIC MODEL sumed to equilibrate rapidly and thus are consid ered to be a single brain compartment. The ex change of radiolabel between compartments is governed by two first-order rate constants, K I and k2' describing transport across the BBB. A third compartment representing metabolized tracer in brain with concentration Cm and the third rate con stant k3' describing the rate of metabolism, becomes unnecessary since ACHC is not metabolized. The solution to the model is written as
THEORY
where K I is the rate constant for transport from plasma to brain (ml g -1 min -I ); equal to CBF times the tracer's single-pass capillary extraction fraction: K I = !Eo, k2 is the rate constant for clear ance of tracer from brain back into plasma (min -I ), X. is the decay constant for the radioisotope ( 1l C), and the symbol Q9 represents mathematical convo lution. As is the case with all two-parameter models of this fo rm, the ratio of the parameters K I and k2 predicts the ratio of the radiotracer's concentration in brain tissue and plasma at equilibrium conditions. This brain-to-plasma ratio is commonly referred to as the tissue DV.
For radiotracers having low single-pass extrac tion fr actions, the radioactivity concentration in blood remains elevated for a longer period of time than for highly extracted radiotracers. Conse quently, the PET data shortly after tracer adminis tration may have a considerable contribution from blood-borne radioactivity (Koeppe et aI., 1987) . The measured PET data are thus the sum of both the tissue and the blood radioactivity components and are written as follows:
where CBV is the cerebral blood volume given as a volume fraction (ml blood ml imaging volume -I ) and Cb1d(t) is the mean radiotracer concentration time course of the cerebral blood pool. The cerebral blood pool has both arterial and venous compo nents as well as red blood cell and plasma compo nents . The arterial blood concentration-time course is measured directly. Red blood cells and plasma are separated and counted, and the hematocrit is determined. Although cerebral venous concentra tion cannot be measured directly, it can be calcu lated (if an iterative parameter estimation technique is used) from the arterial concentration, the esti mates of the parameters KI and k2' and tissue con centration value . A mean vascular concentration time course is then obtained by making an assump tion concerning the relative contributions of arterial and venous blood to the total space in the brain.
Since PET scan values represent integrals of ra dioactivity concentration over the scan's duration and not instantaneous concentrations, the model equations must be integrated over the appropriate time intervals. The ith PET scan of the dynamic sequence is given by
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METHODS

Computer simulations
Simulation studies were performed to examine two possible sources of error in estimates of the kinetic pa rameters. First are uncertainties caused by the statistical nature of PET data, and second are the biases caused by the CBV contribution to the PET measurement of the "tissue" concentration. Simulated noise-free PET data were calculated from the model equations (Eq. 3) using the arterial input shown in Fig. 2 . Transport rate and DV values were varied from 0.015 to 0.050 ml g-I min -I and from 0.7 to 1.1 ml g -I, respectively. Model sensitivity to statistical noise in the measured PET data was analyzed using simulated noisy data. Pseudo-Gaussian noise was added to each individual scan value according to the em pirical relation of Budinger et al. (1978) . Target to-background contrast, relative areas of target and back ground regions, scanner resolution, and total number of coincidence events were all accounted for. Resolution and sensitivity of the TCC PCT-46ooA scanner (see be low) were assumed. Mean values and percentage root mean square errors were calculated from 1,000 indepen dent sets of noisy data. For examination of CBV effects, the blood component was added to the noise-free tissue data. Parameter estimates were then obtained without ac counting for the blood-borne component of the PET data by using Eq. 1. 
Radioisotope
PET amino acid uptake studies were performed using ["C]ACHC, which was synthesized via a Bucherer Strecker reaction of cyclohexanone with H"CN in the presence of ammonium carbonate and ammonium chlo ride according to the method of Hayes et al. (1978) . After purification by ion-exchange chromatography (Fissekis et aI., 1986) , >3.7 GBq (100 mCi) of product (corrected ra diochemical yield �50%) is typically obtained at 40-45 min from the end of bombardment. The [,lC]ACHC was formulated in normal saline solution and sterilized by fil tration prior to administration to the patient. The injec tion volume for a 740-MBq (20-mCi) dose was 5-15 ml and contained a total ACHC mass of 2-5 mg (14-35 !-Lmo!). Reverse-phase HPLC with radiation and ultravi olet (214 nm) was used to determine radiochemical and chemical purity. Radiochemical purity was, in all cases, >98%. The absence of unreacted cyanide was confirmed by a colorimetric assay prior to patient administration.
PET scans
The research protocol was approved by the institu tional review board (human subjects and radioactive drug research committees), and informed consent was ob tained from all subjects prior to participation in the study. PET scans were performed as a dynamic sequence of 15 scans covering a total of 60 min following intravenous injection of 370--740 MBq (10--20 mCi) of ["C]ACHC. Scans were acquired on a TCC PCT -46ooA positron to mograph with in-plane resolution of � 12 mm full width at half-maximum and axial resolution of � 10 mm full width at half-maximum. The total number of coincidence events obtained per direct plane for the 60-min study ranged from 6 to 10 X 106• A single subject was scanned on a Siemens/CTI 931/08-12 high-resolution scanner (in-plane resolution �5.5 mm; axial resolution 7.0--8.0 mm) with a total of �5 x 106 coincidence events acquired. The indi vidual scanning sequence was as follows: five scans x 1 min; four scans x 2.5 min; three scans x 5 min; and three scans x 10 min. Arterial blood samples were drawn from a radial artery at 6-to 10-s intervals for the first 2 min following tracer administration, and then at progressively longer intervals throughout the remainder of the study. Blood samples were centrifuged, and plasma was re moved and counted in a NaI well counter to obtain the arterial plasma input function.
The two-compartment, two-parameter kinetic model was applied to the data, and a rapid pixel-by-pixel weighted integral estimation technique (Alpert et al., 1984) , modified slightly from that originally described, was used for creation of functional images of the model parameters K 1 and k2 and also the amino acid DV. Re gion-of-interest (ROn time sequences of tissue concen tration were also obtained and analyzed in more detail using the nonlinear least-squares estimation procedure of Marquardt (Bevington, 1969) . Different kinetic models were tested, including a model with a third rate constant, k3' representing metabolism of ACHC, a model with a CBV parameter to account for blood-borne radioactivity in the PET data, and a model containing both additional parameters.
Control studies
The 15 young normals studied (aged 19--33 years, mean 26 ± 4 years) received paired ACHC scans during a single scanning session. The first scan was performed as de scribed above, while the second scan occurred 2.0--2.5 h later. Five elderly normals with ages ranging from 52 to 64 years and a mean age of 58 ± 5 years received a single ACHC scan.
Probable AD studies
Seven subjects diagnosed as having probable AD ac cording to the NINCDS criteria (McKhann et al., 1984) received single PET scans. Ages of the patients ranged from 55 to 68 years, with a mean of 63 ± 4 years. Subjects were selected from a group of AD patients with prior fluorodeoxyglucose and [ 1 50]water CBF PET scans that exhibited substantial parietal deficits in cerebral glucose metabolism and blood flow.
PKU study
The single PKU patient, a 36-year-old woman, was scanned twice, using the data acquisition sequence de scribed above. Both studies were performed in the morn ing, the patient having fasted since the previous evening. Scans were acquired at a I-month interval, both immedi ately preceding and then following institution of a 4-week diet restricting phenylalanine intake. Plasma phenylala nine levels of this patient were measured by micro fluorometric assay within 24 h of each PET scan.
RESULTS
Findings from the computer simulation studies are summarized in Tables 1 and 2. Table 1 shows expected parameter uncertainties for transport rate, DV, and clearance rate for a 740-MBq (20-mCi) in jection of e l C]ACHC on the TCC PCT -4600A scan ner. We assume a total of -7.5 million coincidence events are obtained over the 60-min scan duration. Coefficients of variation (COVs) in Kl vary from 5 to 12% over the range of values tested, decreasing as the value of Kl increases. The COY in k2 ranged from 8 to >30%, while the COY in DV ranged from 5 to >40% over the range of values tested. The Simulations were performed for 20 mCi ACHC administration, l-h scan sequence, TCC PCT-4600A scanner characteristics, and 7.5 million total detected coincidence events. Distribution vol ume (DV) is given in ml g-\ K I is given in ml g-I min -I .
estimates of k2 and DV are negatively correlated, and thus the uncertainty in the estimate of their product, K1, is smaller than the uncertainty in either of these parameters. Errors are not highly depen dent on the value of DV except at low transport rates, where a higher DV implies a lower k2 (for fixed K 1 ). At very low values of k 2 ' uncertainties on the estimated parameters become very large as the fitting procedure begins to break down. Table 2 predicts biases in the estimates of K1, k2' Values are the theoretical % bias in the parameter estimates when CBV contributions to the positron emission tomography measurement are not accounted for. Conditions for simulations are shown at the left. K1 values are given as ml g -1 min -1 , while CBV and distribution volume (DV) values are given as ml g -1 .
and DV caused by CBV effects. When the entire data sequence is used in the estimation, both K l and particularly k2 are substantially overestimated when CBV effects are ignored, while their ratio, DV, is underestimated. Note, however, that if the early data fo llowing injection are omitted from the calcu lations, the overestimations in K l and DV can be decreased to a few percent. For example, with 3 min of data omitted from the calculations, bi ases due to CBV of 15% are reduced to between 3 and 4%. Figure 2 shows a typical arterial plasma radioac tivity-time course for e l C]ACHC from one of the normal volunteers . Tracer was administered by in travenous injection over a period of 30-60 s. The arterial plasma radioactivity peaked by 2 min at a concentration of -4 /-LCi ml -1 and showed typical early rapid clearance followed by slow clearance throughout the remainder of the study. Figure 3 shows a typical cortical gray matter ROI time course of ACHC concentration obtained from this same subject. Brain ACHC concentration increases for 20-30 min postinjection, reaching a maximum of -0.5 /-LCi ml-1 for an injected dose of 740 MBq (20 mCi) . After 30 min, a slow net clearance of ACHC is seen, with concentrations at 60 min being -50-80% (decay corrected) of the peak ACHC con centration. Parameters were estimated using itera tive nonlinear least-squares optimization. Figure 3A shows results of a two-parameter fit to the data. The estimated transport rate constant was 0.0388 ml g-l min -1 and the clearance rate constant was 0.0521 min-I, yielding an estimate of 0.744 ml g-l . By adding a blood volume term, a three-parameter fit Fig. 2 . A: Two-parameter fit [K 1 and k2' no cerebral blood volume (CBV)] using the entire data sequence. Triangles represent actual data points and small connected circles indicate the least-squares fit to the data. Note the large residuals in the fit during the first few minutes as shown in the inset. B: Same region-of-interest sequence but using a model with CBV added as an additional fitted parameter. Note the improved fit to the early data. C: Fit as in A, but with the first 3 min of data excluded from the fitting procedure. The fit describes the early uptake even more poorly than the fit shown in A, but because the early data were omitted from the estimation procedure, this discrepancy does not bias the parameter estimates. Note that the parameter estimates are considerably closer to those in B or D, where CBV was included in the model, than to those in A. D: Fit to the data with the parameter k3' included to test the need for a third compartment representing metabolized radiotracer. Note the negligible value of the estimate for k3. DV, distribution volume.
can be plotted as shown in Fig. 3B . The estimate of CBV was 0.027 ml g-I (2.7%), while the estimates of KI and k2 dropped to 0.0354 ml g-I min -I (8.8% decrease) and 0.0463 min -1 (11.1 % decrease), re spectively. An increase to 0.763 ml g-I occurred in the estimate of DV (2.6% increase) . Figure 3C shows results of a two-parameter fit to the data, as in Fig. 3A , but with the first 3 min of data omitted from the estimation procedure. Note that the pa rameter estimates for K 1 , k2' and hence DV are con siderably closer to those from the three-parameter fits shown in Fig. 3B and D than the two-parameter fit shown in Figure 3A . Figure 3D shows the fit and parameter estimates when a third tissue compart ment and additional rate constant, k3' are included in the model. The entire time-tissue course was fit ted, and a fixed CBV value of 0.027 ml g-I was included in the calculations. Note the near-zero es timate for k3 and the relatively unchanged estimates of KI and k2• Table 3 shows the means and standard deviations of the estimates of K 1 , k2' and DV for various brain regions and scalp fr om the first of two scans on the 15 normal volunteers. Values reported in this table were obtained from the parametric images created from the pixel-by-pixel estimation routines. Two parameters were estimated, with the first 3 min of the data fo llowing tracer administration omitted from the calculations. Intersubject regional COVs ranged from 13 to 17%. Since KI = fEo, and typical blood flow values in cortex and subcortical gray matter regions range from 0.6 to 0.8 ml g -1 min -I, the extraction fraction of ACHC appears to be -5-7%. White matter values for KI ranged from 0.020 to 0.025 ml g-I min -I, indicating higher ex traction fractions of -10--15%. Scalp uptake values are similar to brain values, indicating a considerably higher extraction of ACHC in scalp . Figure 4 shows the parametric images of the transport rate constant and DV for the five tomographic levels fr om one young control subject. Note that the gray-white contrast in the transport images is lower than is typically observed in blood flow or glucose metab olism studies. Also apparent is an anterior-to-pos terior gradient in the DV image, which is seen in the majority of subjects scanned.
Intrasubject variability is shown in Table 4 . Given are the mean and standard deviation of the ab solute value of the difference in parameter esti mates between paired baseline PET scans on the young normal volunteers (n = 7) . Hence, both a + 5 and a -5% change register as 5% differences. Note that the mean differences in whole-brain parameter values between scans on a single subject range from 5.4 to 7.3% compared to the COVs across subjects of -15%, calculated from Table 3 . Table 5 shows results across young normals (n = 15), elderly normals (n = 5), and patients with prob able AD (n = 7) . Values are normalized to whole brain averages. Analysis of variance indicated sig nificant group differences only in the caudate nu cleus and putamen. Further analysis comparing groups revealed differences in these regions be tween the AD patients and either young or elderly normal controls, but not between young and elderly controls. Figure 5 shows parametric images of the transport rate constant and DV for a young normal subject, an elderly normal subject, and a patient with advanced AD. Note that both transport rate and DV appear relatively unchanged in parietal and temporal cortex of the AD patient. Figure 6 shows parametric images of both trans port rate and DV for one of five brain levels from the patient with PKU. Plasma phenylalanine levels decreased from 33.4 mg dl -1 at the time of the first scan to 3.4 mg dl -I the day following the repeat study. Normal plasma levels range from 1 to 2 mg dl -I. ACHC transport was severely decreased in the first study with peak brain values of <0. 009 ml g-I min -I, while scalp values were only marginally decreased. DV was also substantially decreased fr om normal . The second scan showed a marked increase in the ACHC uptake rate and some in crease in DV; however, the peak transport rate of -0.022 ml g -1 min -1 was still lower than in any other scan performed thus far on either normal con trol or patient subjects. Figure 7 shows the e IC]ACHC scan performed on the CTI-931108-12 scanner. The injected dose was 1.37 GBq (37 mCi) . Approximately 5 million coincidence events was recorded per direct plane . Data were again analyzed omitting the first 3 min of data acquisition. The increased resolution is readily apparent, particularly in the definition of the scalp and separation of scalp from brain. The increased resolution also makes the blood volume effects near the major vessels more visible.
DISCUSSION
Although numerous animal studies have at tempted to measure amino acid transport across the BBB, there have not been quantitative methods de signed specifically to the measure amino acid trans port and DV in the human brain. Thus, in diseases Given are means:!: SD of the magnitude (sign ignored) of the % differ ence in parameter estimates between first and second scans. Subjects (n = 7) were healthy male volunteers, aged 19--33 years. DV. distribution volume.
for which there are no adequate animal models, such as PKU and AD, it has not been possible to measure directly the effects of the disease process on BBB regulation. Oldendorf et ai . (1971) mea sured brain uptake of e5Se ]selenomethionine with a gamma detector (see below). Work with positron emitter-labeled natural amino acids, such as that by Bustany et ai. (1986) and O'Tuama et al. (1988) with [ ll C]methionine or that by Hawkins (1989) with [ ll C]leucine, provides measures of overall amino acid incorporation. The modeling is complicated by the presence of radiolabeled by-products of amino acid metabolism as well as by the likely incorpora tion of the labeled amino acid into proteins or neu rotransmitters . Thus, the kinetic separation of the BBB transport from subsequent processes is more difficult. The present work demonstrates, for the first time, a quantitative model for the isolated mea surement of amino acid transport measured in vivo in the human brain.
Since [ ll C]ACHC is a nonmetabolized amino acid analogue (Aoyagi et aI., 1988) , a two-compartment, two-rate parameter model was proposed for analy sis of PET data. The computer simulation studies indicated that both amino acid transport rate and DV should be readily estimated by a 60-min dy- Values given are means (SD) and are normalized to whole-brain average. a K1: F = 9.9, p = 0.000 7; DV: F = 5.9, p = 0.0083 (single-factor analysis of variance). b K1: F = 8. 3, p = 0.0018; DV: F = 11.9, p = 0.000 3 (single-factor analysis of variance (left) and distri bution volume (OV; right) in the pa tient with phenylketonuria (PKU). The top pair of images was under prediet conditions with plasma phenylalanine levels of 33.4 mg dl-1 • The bottom pair of images was 4 weeks later following a phenylalanine-restrictive diet with plasma phenylalanine levels of 3.4 mg dl-1 . Note the differences in brain transport and OV between scans, yet the relatively unchanged values for scalp. [l 1 C]ACHC, [l 1 C]aminocyclohex anecarboxylate.
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11 C-ACHC Transport namic study. As would be expected, accuracy of the estimates improves as the rate constant for transport increases. The relatively slow rate of transport of ACHC obviates the need for a large number of rapid early scans. The accuracy of pa rameter estimates did not improve substantially with scan durations shorter than 5 min (simulations not shown) . Thus, the scanning protocol of I-min initial scans provides a more than adequate sam pling rate. The estimate of transport rate can be obtained with reasonable accuracy with as little as 20-30 min of data. However, due to the slow rates of ACHC exchange between plasma and brain, un certainties in the estimates of the DV and clearance rate constant increase as the total scan duration is shortened.
The low e JC]ACHC extraction is reflected in the early PET data by the presence of a high proportion of radioactivity in the vascular space. As shown above, this can lead to significant overestimations of both rate constants, KJ and k2. There are three general means available to address the CBV prob lem. First, one can measure directly the vascular volume from an additional PET scan using esO]CO and make appropriate corrections. Disadvantages of this approach include the extra time and radiation burden of an additional scan to both the patient and the technologist, the need for very precise align ment of images or ROls between esO]CO and [ ll C]ACHC scans , and the inherent uncertainty in the estimate of CBV. A second method is to include an additional model parameter representing the CBV contribution to the total PET signal. This ap proach, however, increases the complexity of the model and adds to the uncertainty in the estimates of the other parameters. A third approach is to omit data obtained early after injection, when blood con centrations of the tracer are much higher than tissue concentrations. This allows rapid pixel-by-pixel es timation of the two rate parameters and thus cre ation of fu nctional images. The major difficulty with this third approach is that the early data also con tain the most information about the transport rate.
For the present initial studies, we rejected the first alternative in an effort to keep the experiment as simple as possible. The computer simulation studies indicated that omission of the first 3 min of data following injection would reduce CBV biases to less than a few percent except in regions in close proximity to major vessels. This suggested that the third approach be investigated further. Both the second and the third approaches were tested with human ACHC PET data. When employing iterative least-squares fitting of ROls (containing many pix-els), either technique appears to adequately remove CBV effects, as is demonstrated in Fig. 3 . How ever, when implementing the pixel-by-pixel rou tines for creation of parametric images, the addition of a third parameter appears to be inferior to omis sion of the first 3 min of data for two reasons. First, the calculation time is increased by a factor of 5 owing to increased model complexity, and second, there is an increase in noise in the functional image of KJ due to fitting a third parameter to individual pixel sequences. The inability to estimate accu rately both CBV and K J on a pixel-by-pixel basis may be attributable partially to the initial I-min scan durations . Since the blood volume component changes rapidly in the early minutes of the study , shorter initial scans may be required to distinguish CBV and KJ adequately . This approach, however, increases the total amount of data that must be ac quired and processed and decreases the statistical quality of each individual scan . Thus, for creation of parametric images of e JC]ACHC transport rate and DV , omission of approximately the first 3 min of data with the use of a two-compartment model with no correction for CBV appears to be the best alternative for kinetic analysis.
The e JC]ACHC PET method, as described above, was applied to a variety of human subjects including controls of differing ages, patients with probable AD , and a single patient with PKU. These studies represent the first applications of the method to the clinical arena and provide initial re sults directed at answering questions in areas of concern such as aging , degenerative brain disor ders , and disorders in amino acid metabolism. Figure 4 illustrates the image quality typically ob tained from a 740-MBq (20-mCi) injection of [ ll C]ACHC. The slow uptake and clearance of the tracer dictate that data be acquired for -60 min fo llowing administration. An unanticipated and un explained feature of the DV images is an apparent anterior-to-posterior gradient. More precisely, the parietal and occipital cortices have a lower DV than the fr ontal and temporal cortices or deep gray mat ter structures. Technical artifacts appear as an un likely explanation, since similar differences have not been detected in DV images derived from other PET agents, such as fluorodeoxyglucose or water. Other reports using e JC]methionine have shown anteroposterior gradients (Heiss et aI ., 1985; Bus tany and Comar, 1985) ; however, these were seen in the incorporation parameter, not the partition co efficient (or DV) parameter, which remained uni fo rm . Furthermore , these incorporation gradients were reversed fr om the finding in our study using ACHC, with occipital and parietal rates being higher than frontal . Their findings were observed in both young and elderly normal controls and also in AD patients.
Whole-brain average values of K I for 15 young normal volunteers ranged from 0.023 to 0.039 ml g-I min -I , with a mean value of 0.033 ml g-I min -I . Assuming normal CBF rates, single-pass ex tractions are only -5-7%. With such small extrac tions, K I reflects mostly capillary permeability and is nearly independent of flow. The cav for mean whole-brain K I of 13.5% is typical of many PET studies and is comparable to intersubject variability reported for either glucose metabolism or blood flow studies (Huang et aI., 1983; Raichle et aI ., 1983; Duara et aI., 1987; Cameron et aI ., 1990; Junck et aI ., 1989 ) . It appears that much of this variability is of a global nature . That is, whatever combination of actual intersubject differences and measurement errors accounts for this variability, the effects are fairly uniform across the brain . This is seen by examining regional transport values nor malized to the whole-brain mean ( Table 5 ) . The Cays in the normalized data are typically <10%. The 15.1% cav for whole-brain DV was similar to that in K I . Again, fo llowing normalization to whole brain DV, intersubject variability was reduced with regional cays of -10%.
Fifteen subjects underwent repeat scans on the same morning. Seven received two baseline scans, while eight received one baseline scan and one scan following ingestion of 34 mg of aspartame/kg body weight. The details of the effect of aspartame on amino acid transport will be presented in a separate publication (Koeppe et al .) . The seven volunteers receiving back-to-back baseline scans provide in formation on the intrasubject variability of ACHC studies. The absolute difference in mean whole brain transport between consecutive studies ranged from <1 to just over 15%, with the average diffe r ence of the seven pairs being 5.4%, as compared with the average difference in mean whole-brain transport between individuals of -15%. This indi cates that paired e I C]ACHC studies are useful in reducing variability of data. Thus, projects that use test-retest protocols, in which the subject serves as his/her own control, will need fewer numbers of subjects to yield significant results than those pro jects requiring different groups of control and test subjects.
Sample size requirements for fu ture studies were predicted using the initial data sets reported in this article and were based on the following assump tions: a 90% probability of detection of differences between test and control groups; a significance level of 0.05; and similarity of the standard devia tions in patient and control populations, 15% for absolute and 8% for normalized data. With the small sample sizes in our test groups, power calcu lations indicate that we would detect absolute dif fe rences of only ;?;28% and normalized differences of ;?;15%. Conversely, future studies designed to detect absolute differences of 30, 20, and 10% be tween groups will require 6, 12, and 48 subjects per group, respectively, while studies designed to de tect normalized differences of 30, 20, and 10% would require only 2, 4, and 14 subjects per group, respectively.
The studies comparing young normal, elderly normal, and AD subjects showed few differences. As mentioned above, this may be due to the limited number of subjects scanned and the necessity to compare across groups. No significant differences in absolute transport rates or DV s were seen be tween young and elderly controls or between either control group and the AD subjects. To reduce vari ability, regional values of K I or DV were normal ized to whole-brain averages. Analysis of variance calculations indicated group differences in both the caudate nucleus and the putamen at the p < 0.01 level. Comparisons between individual groups were performed with Bonferroni-corrected t tests and reached significance (Table 5) , indicating higher basal ganglia-to-cortical ratios of amino acid trans port and DV in probable AD than in controls. Whether this represents cortical deficits (possibly due to atrophy) with preservation of the caudate nucleus and putamen or actual increases in basal ganglia is not at present certain. These findings are consistent with other PET studies using fluorode oxyglucose or water (CBF) that show relative spar ing of the basal ganglia with respect to cortical re gions. In contrast, however, ACHC studies differ fr om those measuring glucose metabolic rates or CBF in that no localized deficits in either transport or DV were detected in the parietal cortex. Each of the AD patients had a previous glucose metabolic scan and most had a prior blood flow study as well. All scans exhibited the typical pattern of severe bi parietal hypometabolism and flow, with relative sparing of the deep gray matter structures, occipital cortex, and cerebellum . In contrast, our results differ from those obtained by Bustany and Comar (1985) using [ l1 C]methionine. They observed that the ratio of frontal to posterior incorporation rates was decreased in AD patients relative to normal elderly controls and that this ratio continued to decline with disease progression. A possible explanation for the different findings may be that ACHC provides an isolated measure of the transport process, while methionine data yield an overall measure of amino acid incorporation rate into protein. Taken together, our studies suggest that the conversion of amino acids in brain into pro teins may be affected in AD , while the delivery of amino acids to the brain remains largely unaffected. The resolution of such issues is the focus of fu ture studies involving e l C]ACHC.
The results from the two scans on the PKU pa tient support the hypothesis that [llC]ACHC mea sures amino acid transport across the BBB. Since the LNAA carrier is near saturation under normal physiological conditions (Smith et aI ., 1987) , a large increase in the plasma concentration of one of the amino acids competing for the carrier would be ex pected to inhibit transport of other amino acids. Phenylalanine has the highest affinity of the natural amino acids for the LN AA carrier, and thus changes in its plasma level would have the greatest inhibitory effe ct among the amino acids. Plasma phenylalanine levels in the PKU patient at the time of the first scan (33.4 mg dl -I ) were �25-30 times normal levels. Calculations using relative affinities of various amino acids from rats (Smith et aI ., 1987) and normal plasma levels for other amino acids pre dict 80% inhibition of ACHC uptake . The mean whole-brain value for K I of the PKU patient was 0.0085 ml g -I min -I , or 74% below the mean of the 15 young normal controls. At the time of the second scan, plasma phenylalanine levels had decreased to 3.4 mg dl -I , but were still a factor of 2.5-3.0 times normal level. The mean whole-brain value for K I increased by a fa ctor of 2.5 to 0.021 ml g-I min -I , but was still 36% below the mean of 15 normal con trols. Further indication that these decreases are due to competitive inhibition from increased plasma phenylalanine levels is that brain uptake was selec tively reduced relative to scalp uptake . The trans port values of scalp did not differ substantially be tween scans, and thus ACHC appears not to depend upon a saturable carrier to pass from plasma to ex tracerebral tissue, such as the scalp.
The study with the PKU patient is of particular interest in terms of the pathophysiology of the men tal retardation seen in this disease. Phenylketonu rics, who are maintained on low phenylalanine dur ing the first years of life , are spared most or all of the debilitating effects of this metabolic disorder in which the enzyme phenylalanine hydroxylase is de ficient. The observed reduction in ACHC uptake of >70% when the PKU subject was on a normal diet is consistent with a substantial block in the uptake of the amino acids that share the LNAA system with phenylalanine, such as leucine, isoleucine, va line, tryptophan, and methionine. Prior studies with C5Se]selenomethionine (Oldendorf et aI., 1971 ) and methionine using a II C label (Bustany et aI ., 1986; O'Tuama et aI ., 1988) have given qualitative indica tions of a block in brain amino acid uptake in phe nylketonurics. The deleterious effect of sustained high plasma phenylalanine during development in untreated PKU is presumably due to this blockade in uptake of one or more of the other essential amino acids. Since the essential amino acids have a broad range of affinities for the transport carrier, and since ACHC has been shown to have an affinity in the middle of this range (Aoyagi et aI ., 1988) , II C-labeled ACHC may be an appropriate probe of the pathological process in PKU-induced mental re tardation.
In conclusion, [ ll C]ACHC appears to be a useful agent for measuring amino acid transport rate and DV in the human brain using dynamic PET. The data were shown to fit a two-compartment, two-rate parameter tracer kinetic model. Inclusion of a third parameter describing the rate of metabolism is not statistically warranted. Both inter-and intrasubject variability are similar to those seen in other com monly performed PET procedures, such as eSF] fluorodeoxyglucose studies of glucose metabolism and [ 1 50]H20 measurement of blood flow. The method should thus prove useful in the study of human neurological disorders .
